No Data
No Data
Express News | Cassava Sciences' Phase 3 Trial Expected To Conclude By December 2024 With 804 Patients; Second Trial With 1,125 Patients To End By June 2025; Successful Results Could Be Revolutionary
Cassava Shares Rise After Incoming Chairman Gives Timeline for Alzheimer's Drug Study Read Out
Cassava Sciences (SAVA) shares were up nearly 24% in recent Monday trading after its recently appointed chairman told shareholders the biotech was expecting the first phase 3 trial read out of
Cassava Sciences Advances Alzheimer's Drug Through High-Stakes Phase 3 Trials
On Monday, Rick Barry, the executive chairman of Cassava Sciences Inc (NASDAQ:SAVA), wrote a letter to shareholders and employees.He said the company is in the final stages of testing its Alzheimer'
Why CrowdStrike Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of CrowdStrike Holdings, Inc. (NASDAQ:CRWD) fell sharply during Monday's session. Guggenheim analyst John Difucci downgraded the stock from Buy to Neutral, while BTIG analyst Gray Powell
IQVIA Posts Upbeat Earnings, Joins Terex, Reddit And Other Big Stocks Moving Higher On Monday
U.S. stocks were higher, with the Nasdaq Composite gaining over 100 points on Monday.Shares of IQVIA Holdings Inc. (NYSE:IQV) rose sharply during Monday's session after the company released better-
Why Cassava Sciences Stock Is Skyrocketing Today